With these latest designations, WHO goes on to expand the growing list of WLAs, which now involves 39 agencies throughout the world, thereby supporting a broader and faster access to quality-assured medical products, especially in low- as well as middle-income countries.

Besides this, the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea, which is one of the first regulatory authorities to complete the WLA evaluation for medicines as well as vaccines in October 2023, has got its listing scope successfully expanded, therefore now covering all the regulatory functions.

According to Dr. Tedros Adhanom Ghebreyesus, who is the director-general of the World Health Organization, this recognition goes on to reflect the deep commitment of these authorities towards regulatory excellence. The designation as new WHO-listed authorities is not just a testament to their robust systems concerning regulations but also a crucial contribution that they make towards global public health. He added that robust and dependable regulators help in ensuring that people across the world have access to effective, safe, and high-quality medical products.

It is well to be noted that almost 70% of the countries across the world still face prominent challenges because of weak or inadequate regulatory systems when it comes to evaluating as well as authorizing their medical products. The WLA framework goes on to promote regulatory convergence and international collaboration, thereby helping the WHO prequalification program and regulatory authorities, especially those who are located in low- and middle-income countries so as to depend on the trusted work as well as the decisions of certain designated agencies. This kind of partnership supports the efficient usage of limited resources, therefore helping with better and faster access in terms of quality-assured, life-saving medical products for billions more people.

The WHO assistant director-general for health systems, access, and data, Dr. Yukiko Nakatani, said that the principle of dependence is indeed central to the approach by WHO towards regulatory systems strengthening and also a cornerstone when it comes to efficient, effective, and smart regulatory oversight of medical products. He further added that new WHO-listed authorities have to be enablers when it comes to promoting transparency, trust, and faster access to medical products that are quality assured, especially when we talk of low- and middle-income countries.

Interestingly, in a world where health threats such as the likes of substandard and falsified medical products exist and know no borders, WLAs happen to serve as crucial pillars of equity and preparedness, thereby making life-saving products available widely, efficiently, and much faster.

The fact is that these designations follow a very stringent performance assessment process, which is carried out by WHO by way of using its worldwide recognized benchmarking and evaluation tools. These assessments were reviewed by the technical advisory group on WLAs – TGA – WLA, which started in June 2025. Apparently, Japan, Canada, and the UK regulatory authorities were in the past recognized as strict regulatory authorities – SRAs. Their designation under the WLA framework goes on to mark a very significant step when it comes to moving beyond the old SRA system but, at the same time, making sure of continuity as well as balance within global procurement processes, which are packed with quality-assured medical products.

The WLA initiative, which was launched in 2022 so as to replace the erstwhile SRA model, offers a transparent and evidence-based pathway when it comes to worldwide recognition of regulatory authorities to help the regulatory convergence and dependence. It builds on decades of the leadership of WHO in order to help the countries to work together in a closer manner on the regulation of medical products and also accelerate access to safe, effective, and quality-assured medical products for everyone around the world.

A Market Set for Transformation

The Medical Laboratory Technology Market can expand strongly, with a compound annual growth rate (CAGR) of over 7.5% during the forecast period. 2034 market valuation expected to mark an exceptional increase due to the trend of advanced technologies including Artificial Intelligence (AI), automation and molecular diagnostics becoming more integrated. Countries like North America, Europe, and Asia-Pacific are leading this industry revolution where investments in healthcare infrastructures is on their conflicting agenda.

Every one of these things is steadily growing which is impressive in a market of continuous chronic disease like diabetes, cancer, and cardiovascular disease, causing the important driving factor for this market. According to the World Health Organization (WHO), 74% of all deaths worldwide are linked to chronic disease. Medical laboratory technologies are the key through which early detection of conditions leads to timely treatment and management needed to squarely face these medical adversaries. As the need for increased diagnostic testing continues to grow, laboratories are implementing advanced technology platforms to enhance accuracy, efficiency, and turnaround time.

The Technological Revolution in Medical Labs

Technological advancements have brought the Medical Laboratory Technology Market to a new horizon of innovations. A growing part of our devices in the laboratory systems that detect the diseases in sequences of genetic molecules — Molecular Diagnostics Examples include real-time polymerase chain reaction (PCR) machines, next-generation sequencing (NGS) and cutting-edge diagnostic tools such as CRISPR.

Artificial Intelligence (AI) and machine learning, are transforming the landscape as well. AI is being used to interpret data, recognize patterns of images, fill in missing pieces and offer predictive diagnostics. Such technologies help improve the accuracy of diagnostics, as well as reducing the load on laboratory technicians, which allows for diagnostics to be performed faster and more accurately. In fact, the 2023 report from Precedence research projects that the integration of AI into laboratory technology is set to become one of the top contributors to the significant growth of the market, driven by increased operational efficiency and reduced operating costs that AI enables to laboratories.

Deepening automation has made laboratories into high-throughput centers. Complete lab automation now approaches sample processing, data entry, and report generation, minimizing human error and improving processing throughput. Such information is vital because during a public health crisis, such as the COVID-19 pandemic, the demand for testing increases exponentially, and the ability to process test results rapidly and accurately is more critical than ever.

Regional Analysis: Where Growth is Happening

The example of market leaders North America reinforces the importance of a robust healthcare infrastructure, high healthcare expenditure, and early adoption of advanced technologies in shaping the Medical Laboratory Technology Market. R&D spending in diagnostic labs, one of the largest sectors of healthcare overall in the US, remains stable and leads to innovation.

Europe is close behind, led by Germany, the United Kingdom and France adopting advanced molecular diagnostics and laboratory automation. As such, this focus on public health initiatives combined with increasing funding for healthcare innovation has set the region firmly on the map.

In contrast, the Asia-Pacific region is seeing rapid growth in the market. Countries including China, India, and Japan are pouring dollars into health care infrastructure to support changing needs as populations grow. The growing prevalence of chronic diseases and increased access to healthcare facilities have rendered this region to be the most lucrative market for diagnostic technologies. Moreover, government efforts to enhance healthcare accessibility and affordability.

Market Dynamics: Opportunities and Challenges

There are challenges to the industry, even as the Medical Laboratory Technology Market is primed for considerable success. The expensive price of these sophisticated devices and the requirement of specialized operators for these devices make it extremely difficult. As a result, smaller laboratories, especially in developing regions, often cannot afford the newest advances, restricting their ability to provide high-quality diagnostic services.

There are also regulatory hurdles, with strict guidelines for the approval and use of new diagnostic tests. While compliance with these standards is critical, it adds to the development costs and time-to-market for manufacturers.

• It also involves recommending the world’s first malaria vaccine.

• The WHO’s REPLACE initiative aims to eliminate trans-fats by 2023.

• About $500 million of PPE has been shipped globally.

• Trans fatty acids are banned for 3.2 billion people in 58 nations.

Despite the COVID-19 outbreak, WHO’s 2020–2021 Results Report highlights the organization’s major achievements throughout the global health continuum. The report, which was published ahead of the World Health Assembly next week starting on May 23, highlights achievements such as the delivery of over 1.4 billion vaccine doses through the COVAX facility, the referral for widespread use of the world’s 1st malaria vaccine, and WHO’s response to 87 health crises, including COVID-19.

Partnering with 1600 technical and operational collaborators, WHO spearheaded the greatest-ever international response to a health crisis between 2020 and 2021, and helped catalyse the world’s largest, fastest, and most complicated inoculation effort. Necessary supplies for the COVID-19 reaction cost the organisation $1.7 billion.

Despite slashed funds and interrupted services, WHO Director-General Dr Tedros Adhanom Ghebreyesus said that even though WHO responded to the most serious global health crisis in a century, it actively supported the Member States in tackling many other risks to health. Even as the world reacts to and recovers from the pandemic throughout the coming years, WHO’s aim is to spend even more funds on their work in countries where it counts the most, he concluded. It is critical for WHO to have stable, consistent, and adaptable funding in order to execute its purpose of promoting health, keeping the world safe, and serving the defenseless.

By January 2022, the ACT-A alliance had distributed over 1 billion COVID-19 vaccination dosages. Nearly $500 million in personal protective equipment was sent globally, along with $187 million in oxygen supplies, $4.8 million in therapies, and 110 million diagnostic tests. However, much work has to be done in order for the world to meet WHO’s goal of inoculating 70% of its people by July 2022.

Beyond pandemic-WHO’s performance

Far beyond the pandemic, the results report demonstrates notable accomplishments. For 3.2 billion individuals in 58 countries, mandatory rules restricting the use of trans fatty acids (a dangerous dietary component linked to cardiovascular disease) have been put in place. Brazil, Peru, Singapore, Turkey, and the United Kingdom are among the 40 countries with best-practice policies. The WHO’s REPLACE effort intends to eliminate trans-fats from the world by the year 2023.

Tobacco usage is declining in 150 countries as a result of steps recommended by the WHO’s Framework Convention on Tobacco Control, saving lives and livelihoods. 15 countries have eliminated HIV and/or syphilis transmission from mother to child as a result of efforts to ramp up life-saving therapies guided by WHO guidelines. Over 1 million children have received the world’s first malaria vaccine (RTS, S), which was recommended by the WHO.

When combined with other malaria control interventions, it is anticipated to prevent 40,000 to 80,000 deaths each year.

An advocate for health equity

The report highlights WHO’s critical position as the world’s global health watchdog, advocating for equality in a planet marked by growing disparities. The pandemic’s devastating consequences were felt worldwide. The report depicts a world that is obviously falling behind on critical international health targets. Countries have fallen behind on WHO’s “Triple Billion objectives,” which provide crucial pathways to achieving the Sustainable Development Goals (SDGs) by 2030, owing to several interruptions created by the COVID-19. Universal health coverage and healthier populations are progressing at approximately a fourth of the rate required to meet the SDG’s by 2030, and no nation was totally prepared for a pandemic of this magnitude.

COVID-19 also caused massive disruptions in health services: 117 of 127 nations examined reported at least one vital health service disruption as a result of COVID, with an average disruption of 45%. The WHO’s ultimate purpose going forward will be to achieve the triple billion targets as a measurable way of closing health equity inequalities.

The relevance of long-term finance

The Results Report outlines WHO’s efforts to improve openness and accountability, as well as expenditure data. The WHO’s programme budget for 2020–2021 was $5,840.4 million. Due to COVID-19 emergency activities, financing totalled $7,916 million. The excess was made possible by the kindness of donors, notably 12 Member States, who gave over 71% of the overall budget. Nonetheless, donors direct the majority of WHO funding through defined voluntary contributions. In 2020-2021, flexible funds accounted for barely 20% of total funding.

The percentage of regular, stable, and predictable finance must increase if WHO is to play its full role in attaining the SDGs, delivering universal health coverage, lowering the burden of disease, and safeguarding 1 billion more individuals from health emergencies.